LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer
Figure 4.AGAP2-AS1 promoted the mobility in CRC cells. (A, B) Representative images of cell migration and invasion after AGAP2-AS1 overexpression or knockdown. *P < 0.05; **P < 0.01.